Physician profile
David I Silbert
NPI 1275593295
$18,676.35
in general payments reported to CMS, 2019-2025
23 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $17K · 2021: $105 · 2022: $455 · 2023: $67.85 · 2024: $486 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16,932.17 | 2019-2022 | |
| Amgen INC. | $296.49 | 2024-2025 | Tepezza |
| Notal Vision, INC. | $246.38 | 2022 | |
| Alcon Vision LLC | $205.60 | 2024-2025 | Clareon |
| Tarsus Pharmaceuticals, INC. | $148.72 | 2024 | Xdemvy |
| Shire North American Group INC | $119.74 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $102.67 | 2024 | Cirrus Hd-Oct |
| Organogenesis INC. | $100.98 | 2022-2025 | Affinity, Puraply |
| Merz Pharmaceuticals, LLC | $96.03 | 2025 | Xeomin |
| Ocular Therapeutix, INC. | $76.61 | 2021-2025 | Dextenza |
| Allergan, INC. | $67.22 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $52.66 | 2023-2024 | Acthar |
| Exact Sciences Corporation | $41.14 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $27.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.36 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.28 | 2021 | |
| Abbvie INC. | $22.88 | 2023 | |
| Biotissue Holdings INC. | $22.29 | 2022 | |
| Thea Pharma INC. | $17.31 | 2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $14.72 | 2020 | |
| Bausch & Lomb Americas INC. | $13.54 | 2024 | Vyzulta |
| Eyevance Pharmaceuticals LLC | $12.52 | 2020 | |
| Travere Therapeutics, INC. | $8.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Silbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.